Cargando…

Evaluation and management of platelet transfusion refractoriness

Platelet transfusion refractoriness (PTR), in which platelet counts do not increase after transfusion, occurs in many patients receiving platelet transfusions. PTR is a clinical condition that can harm patients. The causes of PTR can be divided into two types: immune and non-immune. Most cases of PT...

Descripción completa

Detalles Bibliográficos
Autores principales: Youk, Hee-Jeong, Hwang, Sang-Hyun, Oh, Heung-Bum, Ko, Dae-Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057673/
https://www.ncbi.nlm.nih.gov/pubmed/35483919
http://dx.doi.org/10.5045/br.2022.2021229
_version_ 1784697951402065920
author Youk, Hee-Jeong
Hwang, Sang-Hyun
Oh, Heung-Bum
Ko, Dae-Hyun
author_facet Youk, Hee-Jeong
Hwang, Sang-Hyun
Oh, Heung-Bum
Ko, Dae-Hyun
author_sort Youk, Hee-Jeong
collection PubMed
description Platelet transfusion refractoriness (PTR), in which platelet counts do not increase after transfusion, occurs in many patients receiving platelet transfusions. PTR is a clinical condition that can harm patients. The causes of PTR can be divided into two types: immune and non-immune. Most cases of PTR are non-immune. Among immune causes, the most common is human leukocyte antigen (HLA) class I molecules. PTR caused by anti-HLA antibodies is usually managed by transfusing HLA-matched platelets. Therefore, it is important, especially for hemato-oncologists who frequently perform transfusion, to accurately diagnose whether the cause of platelet transfusion failure is alloimmune or non-immunological when determining the treatment direction for the patient. In this review, we discuss the definitions, causes, countermeasures, and prevention methods of PTR.
format Online
Article
Text
id pubmed-9057673
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
record_format MEDLINE/PubMed
spelling pubmed-90576732022-05-10 Evaluation and management of platelet transfusion refractoriness Youk, Hee-Jeong Hwang, Sang-Hyun Oh, Heung-Bum Ko, Dae-Hyun Blood Res Review Article Platelet transfusion refractoriness (PTR), in which platelet counts do not increase after transfusion, occurs in many patients receiving platelet transfusions. PTR is a clinical condition that can harm patients. The causes of PTR can be divided into two types: immune and non-immune. Most cases of PTR are non-immune. Among immune causes, the most common is human leukocyte antigen (HLA) class I molecules. PTR caused by anti-HLA antibodies is usually managed by transfusing HLA-matched platelets. Therefore, it is important, especially for hemato-oncologists who frequently perform transfusion, to accurately diagnose whether the cause of platelet transfusion failure is alloimmune or non-immunological when determining the treatment direction for the patient. In this review, we discuss the definitions, causes, countermeasures, and prevention methods of PTR. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2022-04-30 2022-04-30 /pmc/articles/PMC9057673/ /pubmed/35483919 http://dx.doi.org/10.5045/br.2022.2021229 Text en © 2022 Korean Society of Hematology https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Youk, Hee-Jeong
Hwang, Sang-Hyun
Oh, Heung-Bum
Ko, Dae-Hyun
Evaluation and management of platelet transfusion refractoriness
title Evaluation and management of platelet transfusion refractoriness
title_full Evaluation and management of platelet transfusion refractoriness
title_fullStr Evaluation and management of platelet transfusion refractoriness
title_full_unstemmed Evaluation and management of platelet transfusion refractoriness
title_short Evaluation and management of platelet transfusion refractoriness
title_sort evaluation and management of platelet transfusion refractoriness
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057673/
https://www.ncbi.nlm.nih.gov/pubmed/35483919
http://dx.doi.org/10.5045/br.2022.2021229
work_keys_str_mv AT youkheejeong evaluationandmanagementofplatelettransfusionrefractoriness
AT hwangsanghyun evaluationandmanagementofplatelettransfusionrefractoriness
AT ohheungbum evaluationandmanagementofplatelettransfusionrefractoriness
AT kodaehyun evaluationandmanagementofplatelettransfusionrefractoriness